Project Oncology® podcast

How ALK Vaccines Could Prolong TKI Response in mNSCLC

0:00
2:15
15 Sekunden vorwärts
15 Sekunden vorwärts
Guest: Angel Qin, MD

Checkpoint inhibitors have shown limited efficacy in ALK+ metastatic non-small cell lung cancer (mNSCLC), but could a different immunologic strategy complement targeted therapy? Dr. Angel Qin discusses the rationale for ALK vaccines and explains how harnessing an ALK-specific immune response may help extend the durability of ALK TKI therapy. She's a Clinical Associate Professor of Internal Medicine at the University of Michigan Medical School.

Weitere Episoden von „Project Oncology®“